Enzymes and Metabolic Biomarkers – Paving the Way to Personalized Therapies
Combining information from genomics, proteomics, and metabolomics to drive early diagnosis, prediction, and therapeutic monitoring.
An ideal biomarker plays an essential role in the early diagnosis, prediction, and therapeutic monitoring of a specific disease, reflecting the burden of the disease for the patients.
Using a biomarker either as a diagnostic tool or in regular monitoring of the disease progression can be of high clinical value for the patients. Biomarkers can be used as a measure of the therapy efficacy and even as a guide for therapy dosage.
CENTOGENE offers rapid medical diagnosis of rare hereditary diseases through the broadest genetic testing portfolio combined with biomarker and enzymatic testing as well as best-in-class interpretation.
The Features of CENTOGENE’s Biomarkers
Monitoring response to treatment
Simplified logistics and analysis in dried blood spots (DBS) with CE-labeled filter card technology (CentoCard®)
High sensitivity and specificity
Short turnaround time
Guiding individualized treatment regimen for improved outcomes
Enzyme activity and biomarker assays can be used for disease diagnosis and novel drug development validation. Enzymes and biochemical biomarker often represent key functions in physiological process. Therefore, they are a powerful tool to reveals early signs of diseases or to streamline disease progress.
- Guide therapeutic regimes
- At-risk cohort testing
Biomarker & ENZYME ASSAYS
- Follow-up monitoring
- Measures disease progression and response to treatment
- Differential diagnosis
First step diagnosis of complex & multi-systemic metabolic diseases
Biomarker/Enzyme + Single Gene Analysis
- Suspected specific disorder
- Clearly definable symptoms
- For comprehensive treatment dicision making
Genetic Panel + Biomarker/Enzyme
- Suspected metabolic disorder
- Complex, overlapping symptoms with broad differential diagnosis
- Abnormal new-born screening results
- Admission to a neonatal intensive care unit
- Symptoms related to neurological conditions of unknown etymology
- Overlapping symptoms with varying age of onset and severity
- Easy to be analyzed using DBS (dried blood spots) technology
- Linked to clinical manifestation
- Quantify easily and reliably in clinical samples
- Reflect realistically the burden of the disease
- Elucidate the molecular pathogenesis of the disease
- Reflect the therapeutic measure outcomes
In complex diseases and disease pathways, a genetic test alone typically can't provide the information needed for a final diagnosis. Therefore, CENTOGENE has pioneered the combination of different tests, like biomarker and multi-biomarker patterns with clear recommendations for testing strategies1. These testing strategies offer you and your patients a faster, more reliable, and more complete solution – providing vital and time-sensitive answers when they matter the most.
|Biomarker testing for pre or post diagnosis
|for the following diseases: Gaucher disease, Fabry disease, Niemann-Pick disease type A/B and type C, AADC deficiency.
|Enzyme activity testing for pre or post diagnosis
|for the following diseases: Gaucher disease, Fabry disease, Pompe disease, Hurler syndrome (MPS I), Hunter syndrome (MPS II), Maroteaux-Lamy syndrome (MPS VI), Morquio syndrome A (MPS IV A), Morquio syndrome B (MPS IV B), Wolman disease, Sanfilippo syndrome B (MPS III B), Alpha-mannosidosis, Beta-mannosidosis, Fucosidosis, Sly syndrome (MPS VII), Tay-Sachs disease, Sandhoff disease, Schindler/Kanzaki disease, Santavuori-Haltia disease, Jansky-Bielschowsky disease
|Comprehensive enzyme activity testing for metabolic diseases
|Four disease specific enzyme panels:
CentoSphingo® (Sphingolipd metabolism)
CentoNCL® (Neuronal ceroid lipofuscinosis)
CentoLSD® (Lysosomal storage disease)
|Biochemical panel + genetic
|Enzyme testing with reflex to genetics
|Four disease specific enzyme panels:
|Genetic panel + biomarker / enzyme
|Testing a comprehensive range of genes first, followed by biochemical testing1
|CentoMetabolic® MOx (~ 200 metabolic disorders)
Fore more information please visit our Multiomic Solutions Webpage.
DisordersTransforming the Management of Metabolic Disorders
Metabolic diseases are a group of rare, inherited diseases characterized by abnormal accumulation of different metabolites in the cells, leading to impaired functioning of the affected cellular organells.
A further subgroup, Lysosomal storage disorders (LSDs), collectively affect 1 in 5,000 live births, with Fabry and Gaucher disease being the most prevalent.2,3,4 It is estimated that every 20 minutes a child is born with an inherited LSD.
CENTOGENE has developed multiple specific biomarkers for certain LSDs with therapeutic options. For example, Lyso-Gb1 has been identified as the most effective biomarker for Gaucher disease.5 All analyses can be done from dried blood spots with CentoCard® and help with the early diagnosis, as well as disease progression and therapeutic monitoring of a specific disorder in the most effective manner.
|Hurler syndrome (MPS I)
|Hunter syndrome (MPS II)
|Maroteaux-Lamy syndrome (MPS VI)
|Morquio syndrome B (MPS IV B)
|Sanfilippo syndrome B (MPS III B)
|Sly syndrome (MPS VII)
|lyso-ceramide trihexoside (lyso-Gb3)
|Niemann-Pick disease type A/B and type C
|SMPD1, NPC1, NPC2
Lyso-Gb1 has been identified as the most precise biomarker for Gaucher disease (GD)5. With a sensitivity and specificity of 100% (see below), it is the optimal biomarker for a sensitive and reliable diagnosis of GD. Evidence of patient data also proves that quantitation of this biomarker can serve as a direct indicator of disease burden and response to treatment for monitoring GD.5
100% sensitivity and 100% specificity of Lyso-Gb1 leading to highest accuracy in patient identification for an optimal diagnosis.
Lyso-Gb1 levels significantly and rapidly increase at time point t5 after a forced treatment break due to temporary unavailability of enzyme replacement therapy. Lyso-Gb1 thereby proves its superb capabilities for monitoring Gaucher disease.
1 Biomarker/Enzyme testing complementary to support the classification of unknown and pathogenic variants.
2 Wittmann, Judit, et al. „Newborn screening for lysosomal storage disorders in Hungary.“ JIMD Reports-Case and Research Reports, 2012/3. Springer, Berlin, Heidelberg, 2012. 117-125.
3 Burlina, Alberto B., et al. „Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy.“ Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism 41.2 (2018): 209-219.
4 Platt, Frances M., et al. „Lysosomal storage diseases.“ Nature Reviews Disease Primers 4.1 (2018): 1-25.
5 Elstein, Deborah, et al. „Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.“ Molecular genetics and metabolism 122.1-2 (2017): 113-120.
An Innovative Approach for Biomarker Discovery
Some genetic disorders, including hereditary angioedema (HAE), do not manifest chronically, but by unpredictable attacks. CENTOGENE has developed a protocol for the collection of patient samples […]
Broader Applicability of Rare Disease Biomarker
Biomarkers have the potential to serve numerous purposes (diagnosis, prognosis, monitoring, etc.) when well-characterized in large cohorts of patients and controls. Building on its rich source of […]
NEW CentoXome®: convirtiendo nuestra experiencia en su ventaja
Los oradores del webinar, la Dra. Pilar Guatibonza, Clinical Genetic Liaison CENTOGENE, y el Dr. Carlos Manrique, Gerente Regional de Ventas en México CENTOGENE, discuten el poder del NEW CentoXome […]
Cómo los biomarcadores transforman los diagnósticos genéticos
A lo largo del seminario web, Pilar Guatibonza, MD, y Carlos Manrique, MD, brindan una descripción general de cómo los biomarcadores multiómicos desempeñan un papel esencial en el diagnóstico […]
How Biomarkers Transform Genetic Diagnostics
Throughout the webinar, Dr. Tobias Böttcher provided an overview of how multiomic biomarkers play an essential role in early diagnosis, prediction, and therapeutic monitoring of Niemann-Pick Disease […]